Uncategorized
EyeGate reports $8.4 million net loss in 2015
EyeGate Pharmaceuticals reported an $8.4 million net loss in 2015 compared with $1.6 million in 2014, according to a company press release. Research and development expenses were reported at $2.7 million in 2015 compared with $0.5 million in 2014. The increase was attributed to clinical activity for EGP-437, the company’s leading drug candidate in clinical trials for treatment of anterior uveitis and macular edema.